Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Corporation

Boston Scientific ( ($BSX) ) has provided an update. On November 18, 2025, Boston Scientific‘s Board of Directors approved the 2026 Annual Bonus Pl...

Boston Scientific Approves 2026 Bonus Plan

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fennec Pharmaceuticals (FENC – Research Report) and ...

Analysts Are Bullish on These Healthcare Stocks: Fennec Pharmaceuticals (FENC), Boston Scientific (BSX)

FST Corp ( ($KBSX) ) has shared an update. FST Corp. has announced its Annual General Meeting of Shareholders scheduled for December 8, 2025, which...

FST Corp. Schedules Virtual Annual Meeting to Approve 2025 Equity Plan

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Boston Scientific (BSX – Research Report) and Coge...

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Cogent Biosciences (COGT)

Blackstone Minerals Ltd ( ($AU:BSX) ) has shared an announcement. Blackstone Minerals Limited has provided an update on its Mankayan Copper-Gold Pr...

Blackstone Minerals Faces Community Challenges at Mankayan Project

An announcement from Blackstone Minerals Ltd ( ($AU:BSX) ) is now available. Blackstone Minerals Limited has announced the appointment of Mr. James...

Blackstone Minerals Appoints New Company Secretary Amid Strategic Expansion

Blackstone Minerals Ltd ( ($AU:BSX) ) has issued an update. Blackstone Minerals Ltd has announced the appointment of Mr. Oliver William Cairns as a...

Blackstone Minerals Ltd Appoints New Director with Significant Interests

An announcement from Blackstone Minerals Ltd ( ($AU:BSX) ) is now available. Blackstone Minerals Limited has announced the cessation of Mr. Hamish ...

Blackstone Minerals Announces Director Departure and Securities Interests

Boston Scientific (($BSX)) announced an update on their ongoing clinical study. Boston Scientific is spearheading a new clinical study titled Prosp...

Boston Scientific’s New Study Targets Weight Regain Post-Gastric Bypass

Boston Scientific (($BSX)) announced an update on their ongoing clinical study. Boston Scientific is currently conducting the Stone and Laser Thera...

Boston Scientific’s SALT Study: A Closer Look at Device Safety and Performance

Boston Scientific (($BSX)) announced an update on their ongoing clinical study. Study Overview: Boston Scientific is conducting a study titled ‘A P...

Boston Scientific’s Innovative Approach to Gastric Outlet Obstruction: Study Update

Boston Scientific (($BSX)) announced an update on their ongoing clinical study. Boston Scientific is currently conducting a study titled ‘A Prospec...

Boston Scientific’s RANGER AV Japan Study: A Promising Development in Hemodialysis Treatment

Boston Scientific (($BSX)) announced an update on their ongoing clinical study. Boston Scientific is currently conducting a study titled ‘cOncomita...

Boston Scientific’s Innovative Approach to Atrial Fibrillation: A Study Update

Boston Scientific (($BSX)) announced an update on their ongoing clinical study. The ADVENT LTO Study, officially titled ‘ADVENT Trial Long Term Out...

Boston Scientific’s ADVENT LTO Study: A Closer Look at Atrial Fibrillation Treatment Progress

Leerink Partners analyst Mike Kratky reiterated a Buy rating on Boston Scientific yesterday and set a price target of $130.00. The company’s shares...

Leerink Partners Reaffirms Their Buy Rating on Boston Scientific (BSX)

Barclays analyst Matt Miksic maintained a Buy rating on Boston Scientific today and set a price target of $136.00. The company’s shares closed yest...

Boston Scientific (BSX) Gets a Buy from Barclays

Boston Scientific ( ($BSX) ) has issued an update. On October 22, 2025, John E. Sununu announced he will not seek re-election to Boston Scientific‘...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BSX	$96.88	+0.29%	13.39M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BSX	$96.88	+0.3%	13.39M
3
4
5
6

BSX

BSX

Get Boston Scientific Corporation Data in Excel

Get Boston Scientific Corporation Data in Excel